•The SEC issued the conditional temporary exemption on September 17, 2026, for trading tokenized shares through automated market makers and liquidity pools.
•A tokenized share bought by a verified person could be transferred to an unverified wallet, the senators warned.
•The exemption runs from September 17, 2026, through September 17, 2031, and the agency has authority to amend it.
•Net loss was $23.7 million, or $0.81 per diluted share, in the quarter ended September 30, 2026.
•Quarterly revenue fell to $12.9 million from $15.1 million a year earlier, and the company attributed the decline to lower AbbVie sales of MAVYRET/MAVIRET.
•Fiscal 2026 revenue was $63.0 million, and net loss was $68.2 million, or $2.35 per diluted share.
•On November 16, 2026, the FDA approved giredestrant with everolimus for patients with advanced estrogen receptor-positive, HER2-negative breast cancer and an ESR1 mutation.
•Median progression-free survival was 10 months with the combination, versus 5.5 months with the comparator treatment; objective response rates were 27% versus 14%.
•The hazard ratio for disease progression or death was 0.38, with statistical significance at p<0.0001.
•Tether Capital announced a $15 million investment in Nomad on November 16, 2026.
•Stablecoins accounted for about 80% of reported crypto-asset trading volume in Brazil during 2025, according to Tether’s account of data from the Federal Revenue Service.
•USD₮ represented 88.7% of reported stablecoin trading volume in Brazil between August 2019 and December 2025, according to Tether.